Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315869 | 1.00 | HTR6 (0.65) | HTR6 | |
| SCHEMBL316488 | 0.91 | HTR6 (0.70) | HTR6 | |
| SCHEMBL316489 | 0.91 | HTR6 (0.70) | HTR6 | |
| SCHEMBL315536 | 0.84 | HTR6 (0.67) | HTR6 | |
| SCHEMBL315535 | 0.84 | HTR6 (0.67) | HTR6 | |
| SCHEMBL23808397 | 0.81 | HTR6 (0.62) | HTR6 | |
| SCHEMBL317134 | 0.79 | HTR6 (1.00) | HTR6 | |
| Hydrochloric Acid SCHEMBL314989 | 0.78 | HTR6 (0.98) | HTR6 | |
| Hydrochloric Acid SCHEMBL314988 | 0.78 | HTR6 (0.98) | HTR6 | |
| SCHEMBL315090 | 0.78 | HTR6 (0.78) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284606-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2021-09-16 | — | — | US | disclosed |
| US-20210284606-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2021-09-16 | — | — | US | disclosed |
| US-20200115333-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2020-04-16 | — | — | US | disclosed |
| US-20200115333-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2020-04-16 | — | — | US | disclosed |
| US-20180319743-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2018-11-08 | — | — | US | disclosed |
| US-20170247321-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247321-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247321-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9670151-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670151-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20080293751-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080293751-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080015256-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
| US-20080015256-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
| US-20080015256-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
| WO-2007147771-A2 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| US-7312359-B2 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | ROCHE PALO ALTO LLC (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312359-B2 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | ROCHE PALO ALTO LLC (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312359-B2 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | ROCHE PALO ALTO LLC (US) | 2007-12-25 | — | — | US | disclosed |
| US-20060167255-A1 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | ROCHE PALO ALTO LLC | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015256-A1 | Tetralin and indane derivatives and uses thereof | INSRR, TTN, INSR | HTR6 1360/4885 |
| US-20060167255-A1 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | HTR2A, HTR1A, HTR5A | HTR6 7/4885 |
| US-20180319743-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | CYP3A7, PARK7, IPO5 | HTR6 939/4885 |
| US-20080293751-A1 | Tetralin and indane derivatives and uses thereof | INSRR, RIF1, TTR | HTR6 1638/4885 |
| US-20210284606-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ERLIN1, INSRR, PSEN1 | HTR6 829/4885 |
| US-20200115333-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ERLIN1, INSRR, PSEN1 | HTR6 829/4885 |
| US-20170247321-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ERLIN1, INSRR, PSEN1 | HTR6 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.